Adma Biologics (ADMA) Interest Expenses (2011 - 2026)
Adma Biologics' (ADMA) quarterly Interest Expenses came in at -$607000.0 in Q4 2025, down 106.84% YoY from $8.9 million in Q4 2024, and down 112.88% on a QoQ basis from $4.7 million in Q3 2025.
Adma Biologics (ADMA) Interest Expenses (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 15 years of Interest Expenses data on file, last reported at -$607000.0 in Q4 2025.
- Quarterly Interest Expenses fell 106.84% year-over-year to -$607000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.5 million (down 21.97% YoY) and the FY2025 annual result came in at $39.4 million, down 42.18% from the prior year.
- Interest Expenses retreated to -$607000.0 in Q4 2025, from $4.7 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $15.4 million in Q2 2025 to a low of -$607000.0 in Q4 2025.
- A 5-year average of $4.9 million and a median of $4.6 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 1812.19% — and 2025, when it tumbled 106.84%.
- Tracing ADMA's Interest Expenses over 5 years: stood at $300000.0 in 2021, then surged by 1812.19% to $5.7 million in 2022, then advanced by 8.34% to $6.2 million in 2023, then soared by 42.69% to $8.9 million in 2024, then plunged by 106.84% to -$607000.0 in 2025.
- The last three Interest Expenses figures came in at -$607000.0 (Q4 2025), $4.7 million (Q3 2025), and $15.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.86 Mn |
| Jun 30, 2026 | 9.86 Mn |
| Dec 31, 2025 | -607,000.00 |
| Dec 31, 2025 | -607,000.00 |
| Sep 30, 2025 | 4.71 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | 15.40 Mn |
| Jun 30, 2025 | 15.40 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Dec 31, 2024 | 8.87 Mn |
| Dec 31, 2024 | 8.87 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 3.78 Mn |
| Jun 30, 2024 | 3.78 Mn |
| Mar 31, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.77 Mn |
| Dec 31, 2023 | 6.22 Mn |
| Dec 31, 2023 | 6.22 Mn |